{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:07:22Z","timestamp":1781626042284,"version":"3.54.5"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study aimed to assess the safety and efficacy of virtual reality (VR) visual stimulation on neuroprotection and neuroenhancement in optic neuropathy patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Open-label, prospective, phase I clinical trial, enrolling 21 participants with glaucoma, plus 1 patient with ischemic optic neuropathy after hydrocephalus. Participants received commercially available VR headsets (HTC Vive or Oculus Rift) for home use loaded with a study-specific visual stimulus program. The VR visual stimulation protocol consisted of up to 1-hour daily sessions, 5 days per week, for 12-week cycles repeatable for up to 24 months. Safety was assessed through adverse event monitoring, and compliance was assessed through self-report. Testing of function (visual acuity and visual field) and structure (optical coherence tomography (OCT) for retinal nerve fiber layer (RNFL) and ganglion cell complex (GCC) thickness) were measured at baseline and follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>VR-based visual stimulation was safe and well tolerated across the 22-patient cohort. Mean baseline intraocular pressure (IOP) was 12.06\u2009\u00b1\u20090.76 mmHg and there was no significant change in IOP at follow-up. 8 of 22 patients were sufficiently compliant with use to analyze for efficacy measures. Analysis of Humphrey visual field (HVF) mean deviation (MD) of individual patients revealed that two eyes of two patients showed improvement and seven eyes of five patients showed worsening during the study duration. One patient using Goldmann visual fields (GVF) demonstrated improvement in sensitivity in both eyes. There were no statistically significant changes in visual acuity, HVF MD, GCC thickness, or RNFL thickness across the full patient population. Two illustrative cases were selected to demonstrate the potential therapeutic effects of VR visual stimulation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings demonstrate that VR-based visual stimulation is safe, well-tolerated, and may provide functional benefits in selected patients. Additional studies are warranted to further investigate this therapeutic approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov, TRN: NCT07071129, Registration date: 9 July 2025, retrospectively registered.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12886-025-04576-w","type":"journal-article","created":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T09:03:03Z","timestamp":1766221383000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Virtual reality stimulation for neuroprotection and neuroenhancement of vision in optic neuropathy patients: a prospective clinical trial"],"prefix":"10.1186","volume":"26","author":[{"given":"Katherine J.","family":"Healzer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasneem Z.","family":"Khatib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gala","family":"Beykin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Wennberg-Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Nu\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Huberman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,20]]},"reference":[{"key":"4576_CR1","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1136\/bjo.2005.081224","volume":"90","author":"HA Quigley","year":"2006","unstructured":"Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262\u20137. https:\/\/doi.org\/10.1136\/bjo.2005.081224..","journal-title":"Br J Ophthalmol"},{"key":"4576_CR2","volume-title":"Webvision: the organization of the retina and visual system","author":"D Kri\u017eaj","year":"1995","unstructured":"Kri\u017eaj D. What is glaucoma? In: Kolb H, Fernandez E, Jones B, Nelson R, editors. Webvision: the organization of the retina and visual system. Salt Lake City (UT): University of Utah Health Sciences Center; 1995.."},{"key":"4576_CR3","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.ophtha.2011.11.003","volume":"119","author":"EE Chang","year":"2012","unstructured":"Chang EE, Goldberg JL. Glaucoma 2.0: Neuroprotection, Neuroregeneration, neuroenhancement. Ophthalmology. 2012;119:979\u201386. https:\/\/doi.org\/10.1016\/j.ophtha.2011.11.003..","journal-title":"Ophthalmology"},{"key":"4576_CR4","doi-asserted-by":"publisher","first-page":"e615","DOI":"10.1111\/aos.12788","volume":"93","author":"F Aptel","year":"2015","unstructured":"Aptel F, Aryal-Charles N, Giraud J-M, El Chehab H, Delbarre M, Chiquet C, et al. Progression of visual field in patients with primary open-angle glaucoma \u2013 ProgF study 1. Acta Ophthalmol. 2015;93:e615\u201320. https:\/\/doi.org\/10.1111\/aos.12788..","journal-title":"Acta Ophthalmol"},{"key":"4576_CR5","doi-asserted-by":"publisher","first-page":"4135","DOI":"10.1167\/iovs.14-14643","volume":"55","author":"BC Chauhan","year":"2014","unstructured":"Chauhan BC, Malik R, Shuba LM, Rafuse PE, Nicolela MT, Artes PH. Rates of glaucomatous visual field change in a large clinical population. Investig Ophthalmol Vis Sci. 2014;55:4135\u201343. https:\/\/doi.org\/10.1167\/iovs.14-14643..","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"4576_CR6","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1167\/iovs.13-13006","volume":"55","author":"LJ Saunders","year":"2014","unstructured":"Saunders LJ, Russell RA, Kirwan JF, McNaught AI, Crabb DP. Examining visual field loss in patients in glaucoma clinics during their predicted remaining lifetime. Investig Ophthalmol Vis Sci. 2014;55:102\u20139. https:\/\/doi.org\/10.1167\/iovs.13-13006..","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"4576_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40123-019-00222-z","volume":"9","author":"A Sheybani","year":"2020","unstructured":"Sheybani A, Scott R, Samuelson TW, Kahook MY, Bettis DI, Ahmed IIK, et al. Open-Angle glaucoma: burden of Illness, current Therapies, and the management of nocturnal IOP variation. Ophthalmol Ther. 2020;9:1\u201314. https:\/\/doi.org\/10.1007\/s40123-019-00222-z..","journal-title":"Ophthalmol Ther"},{"key":"4576_CR8","doi-asserted-by":"publisher","unstructured":"Williams PR, Benowitz LI, Goldberg JL, He Z. Axon regeneration in the mammalian optic nerve. Annu Rev Vis Sci. 2020;6:195\u2013213. https:\/\/doi.org\/10.1146\/annurev-vision-022720-094953.","DOI":"10.1146\/annurev-vision-022720-094953"},{"key":"4576_CR9","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S0896-6273(02)00602-5","volume":"33","author":"JL Goldberg","year":"2002","unstructured":"Goldberg JL, Espinosa JS, Xu Y, Davidson N, Kovacs GTA, Barres BA. Retinal ganglion cells do not extend axons by default: promotion by neurotrophic signaling and electrical activity. Neuron. 2002;33:689\u2013702. https:\/\/doi.org\/10.1016\/S0896-6273(02)00602-5..","journal-title":"Neuron"},{"key":"4576_CR10","doi-asserted-by":"publisher","first-page":"7734","DOI":"10.1523\/JNEUROSCI.5288-11.2012","volume":"32","author":"RG Corredor","year":"2012","unstructured":"Corredor RG, Trakhtenberg EF, Pita-Thomas W, Jin X, Hu Y, Goldberg JL. Soluble adenylyl cyclase activity is necessary for retinal ganglion cell survival and axon growth. J Neurosci. 2012;32:7734\u201344. https:\/\/doi.org\/10.1523\/JNEUROSCI.5288-11.2012..","journal-title":"J Neurosci"},{"key":"4576_CR11","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.ajo.2021.11.002","volume":"234","author":"G Beykin","year":"2022","unstructured":"Beykin G, Stell L, Halim MS, Nu\u00f1ez M, Popova L, Nguyen BT, et al. Phase 1b randomized controlled study of short course topical Recombinant human nerve growth factor (rhNGF) for neuroenhancement in glaucoma: Safety, Tolerability, and efficacy measure outcomes. Am J Ophthalmol. 2022;234:223\u201334. https:\/\/doi.org\/10.1016\/j.ajo.2021.11.002..","journal-title":"Am J Ophthalmol"},{"key":"4576_CR12","doi-asserted-by":"publisher","first-page":"100298","DOI":"10.1016\/j.xops.2023.100298","volume":"3","author":"JL Goldberg","year":"2023","unstructured":"Goldberg JL, Beykin G, Satterfield KR, Nu\u00f1ez M, Lam BL, Albini TA. Phase I NT-501 ciliary neurotrophic factor implant trial for primary Open-Angle glaucoma: Safety, Neuroprotection, and neuroenhancement. Ophthalmol Sci. 2023;3:100298. https:\/\/doi.org\/10.1016\/j.xops.2023.100298..","journal-title":"Ophthalmol Sci"},{"key":"4576_CR13","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1089\/ten.2004.10.1617","volume":"10","author":"CG Thanos","year":"2004","unstructured":"Thanos CG, Bell WJ, O\u2019Rourke P, Kauper K, Sherman S, Stabila P, et al. Sustained secretion of ciliary neurotrophic factor to the Vitreous, using the encapsulated cell Therapy-Based NT-501 intraocular device. Tissue Eng. 2004;10:1617\u201322. https:\/\/doi.org\/10.1089\/ten.2004.10.1617..","journal-title":"Tissue Eng"},{"key":"4576_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1167\/iovs.66.11.3","volume":"66","author":"K Kauper","year":"2025","unstructured":"Kauper K, Nystuen A, Orecchio L, Gonzalez-Lopez E, Lee A, Duncan JL, et al. Long-Term durability of ciliary neurotrophic Factor\u2013Releasing Revakinagene Taroretcel-lwey in individuals with retinal degenerative disorders. Invest Ophthalmol Vis Sci. 2025;66:3. https:\/\/doi.org\/10.1167\/iovs.66.11.3..","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4576_CR15","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/brain\/awv366","volume":"139","author":"B Falsini","year":"2016","unstructured":"Falsini B, Chiaretti A, Rizzo D, Piccardi M, Ruggiero A, Manni L, et al. Nerve growth factor improves visual loss in childhood optic gliomas: a randomized, double-blind, phase II clinical trial. Brain. 2016;139:404\u201314. https:\/\/doi.org\/10.1093\/brain\/awv366..","journal-title":"Brain"},{"key":"4576_CR16","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1177\/1545968310395601","volume":"25","author":"A Chiaretti","year":"2011","unstructured":"Chiaretti A, Falsini B, Servidei S, Marangoni D, Pierri F, Riccardi R. Nerve growth factor eye drop administration improves visual function in a patient with optic glioma. Neurorehabil Neural Repair. 2011;25:386\u201390. https:\/\/doi.org\/10.1177\/1545968310395601..","journal-title":"Neurorehabil Neural Repair"},{"key":"4576_CR17","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1177\/1545968310397201","volume":"25","author":"B Falsini","year":"2011","unstructured":"Falsini B, Chiaretti A, Barone G, Piccardi M, Pierri F, Colosimo C, et al. Topical nerve growth factor as a visual rescue strategy in pediatric optic gliomas: A pilot study including electrophysiology. Neurorehabil Neural Repair. 2011;25:512\u201320. https:\/\/doi.org\/10.1177\/1545968310397201..","journal-title":"Neurorehabil Neural Repair"},{"key":"4576_CR18","doi-asserted-by":"publisher","first-page":"13469","DOI":"10.1073\/pnas.0906678106","volume":"106","author":"A Lambiase","year":"2009","unstructured":"Lambiase A, Aloe L, Centofanti M, Parisi V, Mantelli F, Colafrancesco V, et al. Experimental and clinical evidence of neuroprotection by nerve growth factor eye drops: implications for glaucoma. Proc Natl Acad Sci. 2009;106:13469\u201374. https:\/\/doi.org\/10.1073\/pnas.0906678106..","journal-title":"Proc Natl Acad Sci"},{"key":"4576_CR19","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.neulet.2012.02.003","volume":"519","author":"JL Goldberg","year":"2012","unstructured":"Goldberg JL. Role of electrical activity in promoting neural repair. Neurosci Lett. 2012;519:134\u20137. https:\/\/doi.org\/10.1016\/j.neulet.2012.02.003..","journal-title":"Neurosci Lett"},{"key":"4576_CR20","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.1046\/j.1460-9568.1999.00737.x","volume":"11","author":"M Caleo","year":"1999","unstructured":"Caleo M, Lodovichi C, Maffei L. Effects of nerve growth factor on visual cortical plasticity require afferent electrical activity. Eur J Neurosci. 1999;11:2979\u201384. https:\/\/doi.org\/10.1046\/j.1460-9568.1999.00737.x..","journal-title":"Eur J Neurosci"},{"key":"4576_CR21","doi-asserted-by":"publisher","first-page":"493","DOI":"10.3233\/RNN-2011-0624","volume":"29","author":"BA Sabel","year":"2011","unstructured":"Sabel BA, Fedorov AB, Naue N, Borrmann A, Herrmann C, Gall C. Non-invasive alternating current stimulation improves vision in optic neuropathy. Restor Neurol Neurosci. 2011;29:493\u2013505. https:\/\/doi.org\/10.3233\/RNN-2011-0624..","journal-title":"Restor Neurol Neurosci"},{"key":"4576_CR22","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.4103\/1673-5374.280302","volume":"15","author":"BA Sabel","year":"2020","unstructured":"Sabel BA, Gao Y, Antal A. Reversibility of visual field defects through induction of brain plasticity: vision restoration, recovery and rehabilitation using alternating current stimulation. Neural Regeneration Res. 2020;15:1799. https:\/\/doi.org\/10.4103\/1673-5374.280302..","journal-title":"Neural Regeneration Res"},{"key":"4576_CR23","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s42234-022-00089-9","volume":"8","author":"C Erb","year":"2022","unstructured":"Erb C, Eckert S, Gindorf P, K\u00f6hler M, K\u00f6hler T, Neuhann L, et al. Electrical neurostimulation in glaucoma with progressive vision loss. Bioelectron Med. 2022;8:6. https:\/\/doi.org\/10.1186\/s42234-022-00089-9..","journal-title":"Bioelectron Med"},{"key":"4576_CR24","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/nn.4340","volume":"19","author":"J-HA Lim","year":"2016","unstructured":"Lim J-HA, Stafford BK, Nguyen PL, Lien BV, Wang C, Zukor K, et al. Neural activity promotes long distance, target-specific regeneration of adult retinal axons. Nat Neurosci. 2016;19:1073\u201384. https:\/\/doi.org\/10.1038\/nn.4340..","journal-title":"Nat Neurosci"},{"key":"4576_CR25","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1089\/cyber.2021.0215","volume":"24","author":"J Fan","year":"2021","unstructured":"Fan J, Lu Y, Wiederhold M, Wiederhold B, Chu H, Yan L, Cyberpsychology. Behav Social Netw. 2021;24:683\u20139. https:\/\/doi.org\/10.1089\/cyber.2021.0215..","journal-title":"Behav Social Netw"},{"key":"4576_CR26","unstructured":"The State of Virtual Reality for Glaucoma Care. American Academy of Ophthalmology. 2024. https:\/\/www.aao.org\/eyenet\/article\/virtual-reality-perimetry-and-glaucoma. Accessed 10 July 2025.."},{"key":"4576_CR27","doi-asserted-by":"publisher","first-page":"103010","DOI":"10.1016\/j.apergo.2019.103010","volume":"84","author":"SA Penumudi","year":"2020","unstructured":"Penumudi SA, Kuppam VA, Kim JH, Hwang J. The effects of target location on musculoskeletal load, task performance, and subjective discomfort during virtual reality interactions. Appl Ergon. 2020;84:103010. https:\/\/doi.org\/10.1016\/j.apergo.2019.103010..","journal-title":"Appl Ergon"},{"key":"4576_CR28","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1145\/333329.333344","volume":"32","author":"JJ LaViola","year":"2000","unstructured":"LaViola JJ. A discussion of cybersickness in virtual environments. SIGCHI Bull. 2000;32:47\u201356. https:\/\/doi.org\/10.1145\/333329.333344..","journal-title":"SIGCHI Bull"},{"key":"4576_CR29","doi-asserted-by":"publisher","unstructured":"McCauley ME, Sharkey TJ. Cybersickness: perception of Self-Motion in virtual environments. Presence: Teleoperators Virtual Environ. 1992;1:311\u20138. https:\/\/doi.org\/10.1162\/pres.1992.1.3.311..","DOI":"10.1162\/pres.1992.1.3.311"},{"key":"4576_CR30","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1055\/s-0033-1354602","volume":"33","author":"AM Bronstein","year":"2013","unstructured":"Bronstein AM, Golding JF, Gresty MA. Vertigo and Dizziness from environmental motion: visual Vertigo, motion Sickness, and drivers\u2019 disorientation. Semin Neurol. 2013;33:219\u201330. https:\/\/doi.org\/10.1055\/s-0033-1354602..","journal-title":"Semin Neurol"},{"key":"4576_CR31","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ajo.2017.07.021","volume":"183","author":"X Zhang","year":"2017","unstructured":"Zhang X, Olson DJ, Le P, Lin F-C, Fleischman D, Davis RM. The association between Glaucoma, Anxiety, and depression in a large population. Am J Ophthalmol. 2017;183:37\u201341. https:\/\/doi.org\/10.1016\/j.ajo.2017.07.021..","journal-title":"Am J Ophthalmol"},{"key":"4576_CR32","doi-asserted-by":"publisher","first-page":"325","DOI":"10.62641\/aep.v52i3.1561","volume":"52","author":"J Yin","year":"2024","unstructured":"Yin J, Li H, Guo N. Prevalence of depression and anxiety disorders in patients with glaucoma: A systematic review and Meta-Analysis based on Cross-Sectional surveys. Actas Esp Psiquiatr. 2024;52:325\u201333. https:\/\/doi.org\/10.62641\/aep.v52i3.1561..","journal-title":"Actas Esp Psiquiatr"},{"key":"4576_CR33","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1038\/s41598-021-81512-0","volume":"11","author":"DY Shin","year":"2021","unstructured":"Shin DY, Jung KI, Park HYL, Park CK. The effect of anxiety and depression on progression of glaucoma. Sci Rep. 2021;11:1769. https:\/\/doi.org\/10.1038\/s41598-021-81512-0..","journal-title":"Sci Rep"},{"key":"4576_CR34","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3390\/jpm12040514","volume":"12","author":"A-C Zaharia","year":"2022","unstructured":"Zaharia A-C, Dumitrescu O-M, Radu M, Rogoz R-E. Adherence to therapy in glaucoma Treatment\u2014A review. J Pers Med. 2022;12:514. https:\/\/doi.org\/10.3390\/jpm12040514..","journal-title":"J Pers Med"},{"key":"4576_CR35","doi-asserted-by":"publisher","unstructured":"Garrett B, Taverner T, Gromala D, Tao G, Cordingley E, Sun C. Virtual reality clinical research: promises and challenges. JMIR Serious Games. 2018;6(4):e10839 https:\/\/games.jmir.org\/2018\/4\/e10839. https:\/\/doi.org\/10.2196\/10839.","DOI":"10.2196\/10839"},{"key":"4576_CR36","unstructured":"Schweitzer J, Ibach M, Berdahl J, Daoud M, Daoud YA, Kempinski Y, et al. Peripherex home visual field demonstrates high test-retest reliability | OPTH.."},{"key":"4576_CR37","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.neuron.2008.07.018","volume":"59","author":"AD Huberman","year":"2008","unstructured":"Huberman AD, Manu M, Koch SM, Susman MW, Lutz AB, Ullian EM, et al. Architecture and activity-mediated refinement of axonal projections from a mosaic of genetically identified retinal ganglion cells. Neuron. 2008;59:425\u201338. https:\/\/doi.org\/10.1016\/j.neuron.2008.07.018..","journal-title":"Neuron"},{"key":"4576_CR38","doi-asserted-by":"publisher","unstructured":"Kim US, Mahroo OA, Mollon JD, Yu-Wai-Man P. Retinal ganglion cells\u2014diversity of cell types and clinical relevance. Front Neurol. 2021;12. https:\/\/doi.org\/10.3389\/fneur.2021.661938..","DOI":"10.3389\/fneur.2021.661938"},{"key":"4576_CR39","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1038\/s41467-018-05134-3","volume":"9","author":"BA Rheaume","year":"2018","unstructured":"Rheaume BA, Jereen A, Bolisetty M, Sajid MS, Yang Y, Renna K, et al. Single cell transcriptome profiling of retinal ganglion cells identifies cellular subtypes. Nat Commun. 2018;9:2759. https:\/\/doi.org\/10.1038\/s41467-018-05134-3..","journal-title":"Nat Commun"},{"key":"4576_CR40","doi-asserted-by":"publisher","unstructured":"Sanes JR, Masland RH. The types of retinal ganglion cells: current status and implications for neuronal classification. Annu Rev Neurosci. 2015;38:221\u201346. https:\/\/doi.org\/10.1146\/annurev-neuro-071714-034120.","DOI":"10.1146\/annurev-neuro-071714-034120"},{"key":"4576_CR41","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.neuron.2012.08.041","volume":"76","author":"M Rivlin-Etzion","year":"2012","unstructured":"Rivlin-Etzion M, Wei W, Feller MB. Visual stimulation reverses the directional preference of Direction-Selective retinal ganglion cells. Neuron. 2012;76:518\u201325. https:\/\/doi.org\/10.1016\/j.neuron.2012.08.041..","journal-title":"Neuron"},{"key":"4576_CR42","doi-asserted-by":"publisher","first-page":"5177","DOI":"10.1038\/s41598-021-84437-w","volume":"11","author":"J Paknahad","year":"2021","unstructured":"Paknahad J, Loizos K, Yue L, Humayun MS, Lazzi G. Color and cellular selectivity of retinal ganglion cell subtypes through frequency modulation of electrical stimulation. Sci Rep. 2021;11:5177. https:\/\/doi.org\/10.1038\/s41598-021-84437-w..","journal-title":"Sci Rep"},{"key":"4576_CR43","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1523\/JNEUROSCI.1419-14.2015","volume":"35","author":"RN El-Danaf","year":"2015","unstructured":"El-Danaf RN, Huberman AD. Characteristic patterns of dendritic remodeling in Early-Stage glaucoma: evidence from genetically identified retinal ganglion cell types. J Neurosci. 2015;35:2329\u201343. https:\/\/doi.org\/10.1523\/JNEUROSCI.1419-14.2015..","journal-title":"J Neurosci"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-025-04576-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-025-04576-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-025-04576-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:30:39Z","timestamp":1781623839000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12886-025-04576-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,20]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4576"],"URL":"https:\/\/doi.org\/10.1186\/s12886-025-04576-w","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,20]]},"assertion":[{"value":"6 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in accordance with the ethical principles of the Declaration of Helsinki and was approved by the Stanford Institutional Review Board (Stanford, CA, USA) and registered at ClinicalTrials.gov (NCT07071129). All participants provided written informed consent prior to enrollment, and parents or legal guardians provided written informed consent prior to enrollment for all participants under the age of 16.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40"}}